Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 29 April 1988:
Vol. 240. no. 4852, pp. 646 - 649
DOI: 10.1126/science.2452480
Prev | Table of Contents | Next

Articles

Science, Vol 240, Issue 4852, 646-649
Copyright © 1988 by American Association for the Advancement of Science

articles

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

H Mitsuya, DJ Looney, S Kuno, R Ueno, F Wong-Staal, and S Broder

Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892.

The first step in the infection of human T lymphocytes by human immunodeficiency virus type 1 (HIV-1) is attachment to the target cell receptor, the CD4 antigen. This step may be vulnerable to attack by antibodies, chemicals, or small peptides. Dextran sulfate (molecular weight approximately 8000), which has been given to patients as an anticoagulant or antilipemic agent for more than two decades, was found to block the binding of virions to various target T lymphocytes, inhibit syncytia formation, and exert a potent inhibitory effect against HIV-1 in vitro at concentrations that may be clinically attainable in human beings. This drug also suppressed the replication of HIV-2 in vitro. These observations could have theoretical and clinical implications in the strategy to develop drugs against HIV types 1 and 2.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Polyanionic Microbicides Modify Toll-Like Receptor-Mediated Cervicovaginal Immune Responses.
R. T. Trifonova, G. F. Doncel, and R. N. Fichorova (2009)
Antimicrob. Agents Chemother. 53, 1490-1500
   Abstract »    Full Text »    PDF »
Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors.
D. Daelemans, R. Lu, E. De Clercq, and A. Engelman (2007)
J. Virol. 81, 4381-4385
   Abstract »    Full Text »    PDF »
Development of a New Methodology for Screening of Human Immunodeficiency Virus Type 1 Microbicides Based on Real-Time PCR Quantification.
R. S. Aguiar, L. J. Costa, H. S. Pereira, R. M. Brindeiro, and A. Tanuri (2007)
Antimicrob. Agents Chemother. 51, 638-644
   Abstract »    Full Text »    PDF »
Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides.
G. F. Doncel (2006)
Hum. Reprod. Update 12, 103-117
   Abstract »    Full Text »    PDF »
Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein.
B. Bosch, J. Blanco, E. Pauls, I. Clotet-Codina, M. Armand-Ugon, B. Grigorov, D. Muriaux, B. Clotet, J.-L. Darlix, and J. A. Este (2005)
Antimicrob. Agents Chemother. 49, 4296-4304
   Abstract »    Full Text »    PDF »
A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors.
D. Daelemans, C. Pannecouque, G. N. Pavlakis, O. Tabarrini, and E. De Clercq (2005)
Mol. Pharmacol. 67, 1574-1580
   Abstract »    Full Text »    PDF »
Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents.
S. Bonnenfant, C. M. Thomas, C. Vita, F. Subra, E. Deprez, F. Zouhiri, D. Desmaele, J. d'Angelo, J. F. Mouscadet, and H. Leh (2004)
J. Virol. 78, 5728-5736
   Abstract »    Full Text »    PDF »
Genogroup II Noroviruses Efficiently Bind to Heparan Sulfate Proteoglycan Associated with the Cellular Membrane.
M. Tamura, K. Natori, M. Kobayashi, T. Miyamura, and N. Takeda (2004)
J. Virol. 78, 3817-3826
   Abstract »    Full Text »    PDF »
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry.
J. M. Kilby and J. J. Eron (2003)
N. Engl. J. Med. 348, 2228-2238
   Full Text »    PDF »
Cell surface receptors, virus entry and tropism of primate lentiviruses.
P. R. Clapham and A. McKnight (2002)
J. Gen. Virol. 83, 1809-1829
   Abstract »    Full Text »    PDF »
A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors.
D. Motakis and M. A. Parniak (2002)
Antimicrob. Agents Chemother. 46, 1851-1856
   Abstract »    Full Text »    PDF »
4'-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro.
E.-I. Kodama, S. Kohgo, K. Kitano, H. Machida, H. Gatanaga, S. Shigeta, M. Matsuoka, H. Ohrui, and H. Mitsuya (2001)
Antimicrob. Agents Chemother. 45, 1539-1546
   Abstract »    Full Text »
Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections.
E. De Clercq (2001)
Clin. Microbiol. Rev. 14, 382-397
   Abstract »    Full Text »    PDF »
Superfibronectin, a Multimeric Form of Fibronectin, Increases HIV Infection of Primary CD4+ T Lymphocytes.
M. C. Tellier, G. Greco, M. Klotman, A. Mosoian, A. Cara, W. Arap, E. Ruoslahti, R. Pasqualini, and L. M. Schnapp (2000)
J. Immunol. 164, 3236-3245
   Abstract »    Full Text »    PDF »
Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus.
P. D. Kwong, R. Wyatt, Q. J. Sattentau, J. Sodroski, and W. A. Hendrickson (2000)
J. Virol. 74, 1961-1972
   Abstract »    Full Text »
A Second Target for the Peptoid Tat/Transactivation Response Element Inhibitor CGP64222: Inhibition of Human Immunodeficiency Virus Replication by Blocking CXC-Chemokine Receptor 4-Mediated Virus Entry.
D. Daelemans, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, S. van Dooren, F. Hamy, T. Klimkait, E. de Clercq, and A.-M. VanDamme (2000)
Mol. Pharmacol. 57, 116-124
   Abstract »    Full Text »
Sulfated Polysaccharides and a Synthetic Sulfated Polymer Are Potent Inhibitors of Chlamydia trachomatis Infectivity In Vitro but Lack Protective Efficacy in an In Vivo Murine Model of Chlamydial Genital Tract Infection.
H. Su and H. D. Caldwell (1998)
Infect. Immun. 66, 1258-1260
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir).
J. A. Esté, C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R. F. Rando, B. Clotet, et al. (1998)
Mol. Pharmacol. 53, 340-345
   Abstract »    Full Text »
Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 Glycoprotein.
J. A. Esté, D. Schols, K. De Vreese, K. Van Laethem, A.-M. Vandamme, J. Desmyter, and E. De Clercq (1997)
Mol. Pharmacol. 52, 98-104
   Abstract »    Full Text »
Interaction of HIV-1 Tat Protein with Heparin. ROLE OF THE BACKBONE STRUCTURE, SULFATION, AND SIZE.
M. Rusnati, D. Coltrini, P. Oreste, G. Zoppetti, A. Albini, D. Noonan, F. d'A. di Fagagna, M. Giacca, and M. Presta (1997)
J. Biol. Chem. 272, 11313-11320
   Abstract »    Full Text »    PDF »
Effects of Human Salivas on Recombinant HIV-1 Proteins.
D. W. Archibald, C. A. Hebert, K. L. Gregory, and G. K. Lewis (1993)
Critical Reviews in Oral Biology & Medicine 4, 475-478
   Abstract »    Full Text »    PDF »
Antiretroviral Therapy in AIDS.
S. Broder, H. Mitsuya, R. Yarchoan, and G. N. Pavlakis (1990)
Ann Intern Med 113, 604-618
   Abstract »    PDF »
Molecular targets for AIDS therapy.
H Mitsuya, R Yarchoan, and S Broder (1990)
Science 249, 1533-1544
   Abstract »    PDF »
Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120.
R. Finberg, D. Diamond, D. Mitchell, Y Rosenstein, G Soman, T. Norman, S. Schreiber, and S. Burakoff (1990)
Science 249, 287-291
   Abstract »    PDF »
Human CD4 binds immunoglobulins.
P Lenert, D Kroon, H Spiegelberg, E. Golub, and M Zanetti (1990)
Science 248, 1639-1643
   Abstract »    PDF »
Dextran Sulfate Is Poorly Absorbed after Oral Administration.
K. J. Lorentsen, C. W. Hendrix, J. M. Collins, D. M. Kornhauser, B. G. Petty, R. W. Klecker, C. Flexner, R. H. Eckel, and P. S. Lietman (1989)
Ann Intern Med 111, 561-566
   Abstract »    PDF »
Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.
J. Hildreth and R. Orentas (1989)
Science 244, 1075-1078
   Abstract »    PDF »
Oral Dextran Sulfate (UAOO1) in the Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex.
D. I. Abrams, S. Kuno, R. Wong, K. Jeffords, M. Nash, J.B. Molaghan, R. Gorter, and R. Ueno (1989)
Ann Intern Med 110, 183-188
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)